Lactobacillus helveticus R0052 alleviates liver injury in D-galactosamine treated rats

Liver is an important digestive gland and acute liver failure will result in high mortality. Probiotics are considered as potential adjuvant therapy for liver disease. This study aims to investigate the beneficial effects of Lactobacillus helveticus R0052 on acute liver injury as well as the underlying mechanisms. Sprague-Dawley rats were pretreated by gavage of L. helveticus R0052. Subsequently, acute liver injury was induced by intraperitoneal injection of D-galactosamine. The gut microbiome of three experimental groups, named as normal control (NC) group, positive control (PC) group and L. helveticus R0052 treated (R0052) group, was studied